Close Menu

NEW YORK (GenomeWeb) – Leerink today downgraded Foundation Medicine's shares following Roche's announcement that it will acquire a majority stake in the cancer genomics diagnostics firm. 

Analyst Dan Leonard downgraded Foundation to Market Perform from a previous Outperform rating, while he raised the target price on the company's shares to $50 from $30. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.